Description

In this webinar, which took place on 13 September 2022, Thijs Barten, Joost PH Drenth, Frederik Nevens and Richard Taubert discuss how the new EASL Guidelines on the management of cystic liver diseases has been created and they will also highlight some of the cases that are presented in the guidelines.

Targeted Audience

  • General practitioners
  • Hepatologists
  • Oncologists
  • Health care professionals

Speakers

barten Thijs Barten is a physician researcher of Gastroenterology and Hepatology at Radboud University Medical Center. His PhD focusses on polycystic liver disease.
drenth Joost PH Drenth is a Hepatologist and the current chair of the Department of Gastroenterology and Hepatology of the Radboudumc, Nijmegen, The Netherlands. He serves as part of committees of professional organisations at the national as well as the European level such as European Rare diseases Network (ERN). He serves the World Gastroenterology Organisation as chair of the clinical research committee and is the acting chair of the Dutch Association of Hepatology. He is the current editor-in-chief of the UEG journal (Impact Factor 6.9). He has created scientific networks and initiated national research programs on infectious hepatitis (HepNed) and autoimmune hepatitis.
nevens Frederik Nevens is Professor of Medicine at the KU Leuven, Belgium. He is senior Hepatologist and the Medical Director of the Liver Transplant program at the University Hospitals Leuven (Belgium). He is currently the coordinator of the courses of Digestive Diseases at the University of Leuven (KUL). He is author/co-author of > 800 publications (web of science) with a sum of times cited of 20 000 and he was the presenter of >500 lectures at national and international scientific meetings (including EASL, AASLD, Best of EASL speaker and Gastro Update Europe).
taubert Richard Taubert is gastroenterologist and hepatologist at the Dept. Gastroenterology, Hepatology and Endocrinology of the Hannover Medical School in Hannover/Germany. His clinical focus is the care of patients with rare and end-stage liver diseases before and after liver transplantation. His research focuses on immune mediated liver diseases before and after transplantation. He serves as the Hannover Medical School representative of the European Reference Network on rare liver diseases.
Log in to post comments